SCHEMBL2510367

SCHEMBL2510367

Cc1ccc(Cl)cc1N1CCN(CCCN2C(=O)c3ccccc3C2=O)CC1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 2/20 0.73
ADRA1A P35348 2/20 0.73
ADRA1B P35368 2/20 0.73
DRD2 P14416 3/20 0.60
DRD3 P35462 3/20 0.60
DRD4 P21917 2/20 0.60
ALDH1A1 P00352 3/20 0.58
HTR1A P08908 2/20 0.58
MEN1 O00255 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
ALOX12 P18054 1/20 0.57
HTR7 P34969 1/20 0.57
KMT2A Q03164 1/20 0.57
HIF1A Q16665 1/20 0.57
HSD17B10 Q99714 1/20 0.57
KDM4E B2RXH2 1/20 0.56
GLA P06280 1/20 0.56
HPGD P15428 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2315895 0.98 ADRA1D (0.73) ADRA1DADRA1AADRA1BDRD2DRD3
Hydrochloric Acid SCHEMBL9987656 0.97 ADRA1D (0.72) ADRA1DADRA1AADRA1BDRD2DRD3
SCHEMBL6577731 0.93 ADRA1B (0.76) ADRA1DADRA1AADRA1BDRD2DRD3
SCHEMBL6771089 0.85 DRD2 (0.76) ADRA1DADRA1AADRA1BDRD2DRD3
SCHEMBL10835924 0.85 DRD2 (0.71) ADRA1DADRA1AADRA1BDRD2DRD3
SCHEMBL21802151 0.84 DRD2 (0.70) ADRA1DADRA1AADRA1BDRD2DRD3
SCHEMBL2316845 0.83 ADRA1B (0.66) ADRA1DADRA1AADRA1BALDH1A1HTR1A
SCHEMBL2318212 0.83 ADRA1B (0.66) ADRA1DADRA1AADRA1BALDH1A1HTR1A
SCHEMBL2316840 0.83 ADRA1B (0.66) ADRA1DADRA1AADRA1BALDH1A1HTR1A
SCHEMBL13484830 0.83 HTR1A (0.71) ADRA1DADRA1AADRA1BDRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10421763-B2 Compositions of protein receptor tyrosine kinase inhibitors PURDUE PHARMA L.P. (US) 2019-09-24 US disclosed
US-10421763-B2 Compositions of protein receptor tyrosine kinase inhibitors PURDUE PHARMA L.P. (US) 2019-09-24 US disclosed
US-20180086777-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS PURDUE PHARMA L.P. (US) 2018-03-29 US disclosed
US-20180086777-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS PURDUE PHARMA L.P. (US) 2018-03-29 US disclosed
US-9738659-B2 Compositions of protein receptor tyrosine kinase inhibitors PURDUE PHARMA L.P. (US) 2017-08-22 US disclosed
US-9738659-B2 Compositions of protein receptor tyrosine kinase inhibitors PURDUE PHARMA L.P. (US) 2017-08-22 US disclosed
US-9738659-B2 Compositions of protein receptor tyrosine kinase inhibitors PURDUE PHARMA L.P. (US) 2017-08-22 US disclosed
US-20150218188-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM PHARMA LLC (US) 2015-08-06 US disclosed
US-20150218188-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM PHARMA LLC (US) 2015-08-06 US disclosed
US-20150218188-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM PHARMA LLC (US) 2015-08-06 US disclosed
US-8809530-B1 Compositions of protein receptor tyrosine kinase inhibitors VM PHARMA LLC (US) 2014-08-19 US disclosed
US-20140228331-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS PURDUE PHARMA L.P. 2014-08-14 US disclosed
US-20140228331-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS PURDUE PHARMA L.P. 2014-08-14 US disclosed
US-20140228331-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS PURDUE PHARMA L.P. 2014-08-14 US disclosed
US-20110301133-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM PHARMA LLC (US) 2011-12-08 US disclosed
US-20110301133-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM PHARMA LLC (US) 2011-12-08 US disclosed
US-20110301133-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM PHARMA LLC (US) 2011-12-08 US disclosed
EP-2376495-A2 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM Pharma LLC (US) 2011-10-19 EP disclosed
WO-2010077680-A2 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM DISCOVERY INC. (US) 2010-07-08 WO disclosed
WO-2010077680-A2 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS VM DISCOVERY INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218188-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS NGFR, NGF, GRB2 ADRA1D 1950/4885ADRA1A 2175/4885ADRA1B 2077/4885
US-10421763-B2 Compositions of protein receptor tyrosine kinase inhibitors NGFR, NGF, GRB2 ADRA1D 1950/4885ADRA1A 2175/4885ADRA1B 2077/4885
US-20140228331-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS NGFR, NGF, GRB2 ADRA1D 1950/4885ADRA1A 2175/4885ADRA1B 2077/4885
US-20180086777-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS NGFR, NGF, GRB2 ADRA1D 2099/4885ADRA1A 2408/4885ADRA1B 2343/4885
US-20110301133-A1 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS NGFR, NGF, GRB2 ADRA1D 1950/4885ADRA1A 2175/4885ADRA1B 2077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.